Cell line · CVCL_4056
Papers32
1 to 20 of 32
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Chrysosplenetin-induced TMED3 aggregation triggers unfolded protein response in pancreatic cancer. | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeted degradation of USP7 in solid cancer cells reveals distinct effects of deubiquitinase degraders and inhibitors. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| IFN-γ-driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Small-molecule modulators of B56-PP2A restore 4E-BP function to suppress eIF4E-dependent translation in cancer cells. | J Clin Invest | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparib. | Cell Death Discov | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Vitamin B6 Competition in the Tumor Microenvironment Hampers Antitumor Functions of NK Cells. | Cancer Discov | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function. | Mol Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines. | Sci Rep | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Chimeric antibody targeting unique epitope on onco-mucin16 reduces tumor burden in pancreatic and lung malignancies. | NPJ Precis Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Solid Cancers with a Cancer-Specific Monoclonal Antibody to Surface Expressed Aberrantly O-glycosylated Proteins. | Mol Cancer Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy. | Front Oncol | 2022 | Its Methods give the RRID and name the line | PubMed | |
| MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. | Mol Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling. | Mol Cancer Ther | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression. | Gut | 2022 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_4056/papers